Project Grant R01CA293672
Award Date
2/24/25
Completion Date
1/31/30
Dollars Obligated
$616K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research to develop and evaluate Antibody-Drug Conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The total funding amount is $215,311 for the period from March 10, 2025 to February 28, 2027. The key objectives are to generate GPR56-targeted ADCs, assess their efficacy and safety in preclinical TNBC models, and evaluate the...
The University of Texas Health Science Center of San Antonio (UTHSCSA) received a $978,159 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant supports research into purinergic receptor antagonist therapeutics for treating metastatic renal cancer from July 1, 2023 through June 30, 2026. As the prime awardee, UTHSCSA will conduct research to develop medical solutions for cancer on the battlefield and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Virginia Commonwealth University provides $622,329 to conduct research aimed at modulating the growth, progression, and metastasis of triple-negative breast cancer (TNBC) by inhibiting the MDA-9 protein. The key objectives are to: 1) formulate a small molecule inhibitor of MDA-9 called PDZ1I-Nano for clinical use and characterize its non-cell-autonomous anti-tumor effects, particularly on...
The National Cancer Institute (NCI) awarded a $667,792 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Chicago. The five-year grant, running from June 1, 2024 to May 31, 2029, will fund research to develop "ultra-potent, pharmacologically stable" synthetic transcriptional repressors (STRs) that can directly inhibit the oncogenic activity of the transcription factors XBP1 and HIF1A. These targets are critical for the survival and growth of...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027....
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on activating TFEB, a transcription factor, to enhance the efficacy of immunotherapy for triple negative breast cancer (TNBC). The $400,000 award supports two specific aims: 1) evaluating the toxicity and pharmacokinetics of the TFEB activator compound USCYL01 in vitro and in vivo, and 2) testing USCYL01 as an agent to enhance the efficacy of immune checkpoint inhibitor (ICI) plus...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $676,584 to The University of Texas MD Anderson Cancer Center to conduct research aimed at understanding the co-evolution of cancer subclones and their tumor microenvironment in metastatic triple-negative breast cancer (MTNBC). The key objectives are to: 1) Study the genomic and phenotypic evolution of metastatic precursor cells during dissemination, 2) Investigate gene expression...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $802,230 to the University of Texas Health Science Center at Houston (UTHealth) to conduct research aimed at understanding and overcoming resistance of breast cancer brain metastases to RET inhibition. The key objectives are to: Determine the role of the TGLI1 gene in mediating resistance of breast cancer brain metastases to RET inhibition. Evaluate whether dual targeting of RET and...
This federal Project Grant award, provided by the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to define the role of the RCOR2 gene in hypoxia-induced immune evasion and its potential therapeutic applications for triple-negative breast cancer. The $1.64 million award, effective from June 1, 2024 through May 31, 2027, will support...